期刊
JOURNAL OF GLOBAL INFECTIOUS DISEASES
卷 2, 期 2, 页码 159-166出版社
MEDKNOW PUBLICATIONS & MEDIA PVT LTD
DOI: 10.4103/0974-777X.62886
关键词
Kala-azar; Liposomal; Amphotericin B
资金
- NIAID
- NIH TMRC [1P50AI074321-01]
Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection. Although there is a regional variation in the susceptibility of the parasite a total dose of 20 mg/kg is effective in immunocompetent patients. Randomized clinical trials of liposomal amphotericin B in the treatment and secondary prophylaxis of HIV-VL coinfected patients is urgently needed to optimize treatment in this subset. With the availability of Liposomal amphotericin B at a preferential pricing in the endemic areas, short course combination therapy can become a viable alternative.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据